Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2022 | The promise of targeted combination therapies in CLL & their impact on immune function

Clare Sun • 29 Sep 2022
SOHO 2022
Chronic Lymphocytic Leukemia Leukemia

Clare Sun, MD, National Institutes of Health, Bethesda, MD, shares her excitement for clinical trials evaluating targeted therapy combinations in chronic lymphocytic leukemia (CLL), highlighting the importance of investigating the impact these therapies may have on the immune system. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Research funding: Genmab

More from Clare Sun

3:41
Supportive care for infectious complications in CLL
Clare Sun • 29 Sep 2022
2:03
The importance of improving immune function in CLL
Clare Sun • 29 Sep 2022
1:14
Exciting updates in CLL and the importance of immune characterization
Clare Sun • 29 Sep 2022
4:54
What leads to shorter progression-free survival in CLL patients?
Clare Sun • 12 May 2017

Related Videos

1:40
The role of CPX-351 in the AML treatment landscape & insights into the AMLSG 30-18 trial
Felicitas Thol • 19 Apr 2024
3:21
Integrating genomics and MRD in transplant decision-making for patients with AML
Jurjen Versluis • 22 Apr 2024
4:19
Blinatumomab to achieve remission and consolidation with haploSCT for pediatric ALL
Alberto Olaya-Vargas • 15 Apr 2024
3:32
Improving CAR-T therapy for ALL & lymphoma: allogeneic products & reducing CRS/ICANS
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals